Literature DB >> 10929768

Adamantiades-Behçet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells.

C C Zouboulis1, J Katsantonis, R Ketteler, R Treudler, E Kaklamani, S Hornemann, P Kaklamanis, C E Orfanos.   

Abstract

The serum levels of several cytokines were determined in 94 patients with Adamantiades-Behçet's disease (ABD), aged 36.1+/-11.0 years, during the active stage (n = 75) and the inactive stage (n = 19) of the disease. A group of 75 healthy individuals matched for age and sex served as controls. Cytokine levels were determined using commercially available ELISA kits. Of the 75 patients with active disease and 19 with inactive disease, 38 (51%) and 4 (21%), respectively, and 23 healthy controls (31%) were found to have detectable levels of interleukin 8 (IL-8) in their serum (P < 0.05). Also, increased IL-8 serum levels were found in patients with active disease (median 12 pg/ml, P = 0.010) compared to patients with inactive disease (< or = 10 pg/ml) and to healthy controls (< or = 10 pg/ml). In particular, patients with oral aphthous ulcers (n = 51, 34 pg/ml) and neurological features (n = 4, 71 pg/ml) exhibited increased IL-8 levels. In contrast, there was no correlation between disease activity and the serum levels of IL-1alpha, IL-1beta, tumor necrosis factor alpha (TNF-alpha), soluble intercellular adhesion molecule-1 or basic fibroblast growth factor (bFGF). In a second set of experiments, the involvement of dermal microvascular endothelial cells in IL-8 secretion was investigated. Immortalized human dermal microvascular endothelial cells (HMEC-1 cells) were maintained for 4 h in vitro with serum from 18 ABD patients or with IL-1beta, a known stimulator of IL-8 synthesis, TNF-alpha or their combination at five- to tenfold higher concentrations than those found in the serum of ABD patients. Increased IL-8 secretion was found after incubation with ABD patients' serum (median 20 pg/ml), but IL-1beta, TNF-alpha and IL-1beta + TNF-alpha failed to induce IL-8 secretion by HMEC-1 cells (< or = 1-1.2 pg/ml) in biologically relevant concentrations. Our study showed increased IL-8 serum levels in ABD patients with active oral and neurological manifestations. Human microvascular endothelial cells may, at least partially, be responsible for the enhanced IL-8 secretion in the active stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929768     DOI: 10.1007/s004030000128

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  20 in total

Review 1.  Pathogenesis of Adamantiades-Behçet's disease.

Authors:  Christos C Zouboulis; Tobias May
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

2.  The distinct expressions of interleukin-15 and interleukin-15 receptor α in Behçet's disease.

Authors:  Jung-Yoon Choe; Hwajeong Lee; Sang Gyung Kim; Min Ji Kim; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2013-02-17       Impact factor: 2.631

3.  Promoter -2518 single nucleotide polymorphism of monocyte chemoattractant protein-1 is associated with clinical severity in Behçet's disease.

Authors:  Seong-Kyu Kim; Won-Cheoul Jang; Young-Chang Ahn; Sang-Hyun Lee; Shin-Seok Lee; Jin-Wuk Hur
Journal:  Inflamm Res       Date:  2012-04-03       Impact factor: 4.575

Review 4.  Pediatric Behçet's disease - clinical aspects and current concepts.

Authors:  Mehmet Yıldız; Oya Köker; Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Eur J Rheumatol       Date:  2019-09-05

Review 5.  Advances in therapy for ANCA-associated vasculitis.

Authors:  Duvuru Geetha; Philip Seo
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 6.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

Review 7.  Neonatal Behçet's disease without maternal history.

Authors:  Yung-Sen Chang; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rheumatol       Date:  2011-08-26       Impact factor: 2.980

Review 8.  Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations.

Authors:  Violetta D Kapsimali; Meletios A Kanakis; George A Vaiopoulos; Phaedon G Kaklamanis
Journal:  Clin Rheumatol       Date:  2010-05-22       Impact factor: 2.980

9.  Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet's disease.

Authors:  Fuat Erdem; Mehmet Gündoğdu; Ilhami Kiki; Refik Ali Sari; Ahmet Kiziltunç
Journal:  Rheumatol Int       Date:  2004-07-15       Impact factor: 2.631

Review 10.  Mucocutaneous lesions of Behcet's disease.

Authors:  Erkan Alpsoy; Christos Constantin Zouboulis; George Edward Ehrlich
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.